170 related articles for article (PubMed ID: 31577961)
1. The molecular biology of pancreatic neuroendocrine neoplasms: Challenges and translational opportunities.
Young K; Starling N; Sadanandam A
Semin Cancer Biol; 2020 Apr; 61():132-138. PubMed ID: 31577961
[TBL] [Abstract][Full Text] [Related]
2. The evolving (epi)genetic landscape of pancreatic neuroendocrine tumours.
Pipinikas CP; Berner AM; Sposito T; Thirlwell C
Endocr Relat Cancer; 2019 Aug; 26(9):R519-R544. PubMed ID: 31252410
[TBL] [Abstract][Full Text] [Related]
3. Molecular subtyping in pancreatic neuroendocrine neoplasms: New insights into clinical, pathological unmet needs and challenges.
Yan J; Yu S; Jia C; Li M; Chen J
Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188367. PubMed ID: 32339609
[TBL] [Abstract][Full Text] [Related]
4. Molecular profile of pancreatic neuroendocrine neoplasms (PanNENs): Opportunities for personalized therapies.
Arakelyan J; Zohrabyan D; Philip PA
Cancer; 2021 Feb; 127(3):345-353. PubMed ID: 33270905
[TBL] [Abstract][Full Text] [Related]
5. Pancreatic Neuroendocrine Neoplasms: Landscape and Horizon.
Tang LH
Arch Pathol Lab Med; 2020 Jul; 144(7):816-828. PubMed ID: 32298138
[TBL] [Abstract][Full Text] [Related]
6. P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms.
Nielsen K; Binderup T; Langer SW; Kjaer A; Knigge P; Grøndahl V; Melchior L; Federspiel B; Knigge U
BMC Cancer; 2020 Jan; 20(1):27. PubMed ID: 31924180
[TBL] [Abstract][Full Text] [Related]
7. Survival comparison between primary hepatic neuroendocrine neoplasms and primary pancreatic neuroendocrine neoplasms and the analysis on prognosis-related factors.
Li MX; Li QY; Xiao M; Wan DL; Chen XH; Zhou L; Xie HY; Zheng SS
Hepatobiliary Pancreat Dis Int; 2019 Dec; 18(6):538-545. PubMed ID: 30981633
[TBL] [Abstract][Full Text] [Related]
8. Application of multiomics sequencing and advances in the molecular mechanisms of pancreatic neuroendocrine neoplasms.
Jiang R; Hong X; Zhao Y; Wu W
Cancer Lett; 2021 Feb; 499():39-48. PubMed ID: 33246093
[TBL] [Abstract][Full Text] [Related]
9. Advances in the cytologic diagnosis of gastroenteropancreatic neuroendocrine neoplasms.
Sigel CS
Cancer Cytopathol; 2018 Dec; 126(12):980-991. PubMed ID: 30485690
[TBL] [Abstract][Full Text] [Related]
10. Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas.
Oronsky B; Ma PC; Morgensztern D; Carter CA
Neoplasia; 2017 Dec; 19(12):991-1002. PubMed ID: 29091800
[TBL] [Abstract][Full Text] [Related]
11. A Clinicopathologic and Molecular Update of Pancreatic Neuroendocrine Neoplasms With a Focus on the New World Health Organization Classification.
Fang JM; Shi J
Arch Pathol Lab Med; 2019 Nov; 143(11):1317-1326. PubMed ID: 31509453
[TBL] [Abstract][Full Text] [Related]
12. Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms.
Janson ET; Sorbye H; Welin S; Federspiel B; Grønbæk H; Hellman P; Ladekarl M; Langer SW; Mortensen J; Schalin-Jäntti C; Sundin A; Sundlöv A; Thiis-Evensen E; Knigge U
Acta Oncol; 2014 Oct; 53(10):1284-97. PubMed ID: 25140861
[TBL] [Abstract][Full Text] [Related]
13. Medical Treatment of Advanced Pancreatic Neuroendocrine Neoplasms.
Palmieri LJ; Dermine S; Barré A; Dhooge M; Brezault C; Cottereau AS; Coriat R
J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32549203
[TBL] [Abstract][Full Text] [Related]
14. Pancreatic Neuroendocrine Neoplasms: Basic Biology, Current Treatment Strategies and Prospects for the Future.
Ohmoto A; Rokutan H; Yachida S
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28098761
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of tumour burden in stage IV neuroendocrine neoplasia: A comparison between pancreatic and gastrointestinal localizations.
Panzuto F; Pusceddu S; Faggiano A; Rinzivillo M; Brighi N; Prinzi N; Riccardi F; Iannicelli E; Maggio I; Femia D; Tafuto S; Manuzzi L; Di Sarno A; Annibale B; de Braud F; Campana D;
Pancreatology; 2019 Dec; 19(8):1067-1073. PubMed ID: 31587962
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic neuroendocrine neoplasms: The latest surgical and medical treatment strategies based on the current World Health Organization classification.
Ishida H; Lam AK
Crit Rev Oncol Hematol; 2020 Jan; 145():102835. PubMed ID: 31864179
[TBL] [Abstract][Full Text] [Related]
17. ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas.
Garcia-Carbonero R; Sorbye H; Baudin E; Raymond E; Wiedenmann B; Niederle B; Sedlackova E; Toumpanakis C; Anlauf M; Cwikla JB; Caplin M; O'Toole D; Perren A;
Neuroendocrinology; 2016; 103(2):186-94. PubMed ID: 26731334
[No Abstract] [Full Text] [Related]
18. Biomarkers for Pancreatic Neuroendocrine Neoplasms (PanNENs) Management-An Updated Review.
Bocchini M; Nicolini F; Severi S; Bongiovanni A; Ibrahim T; Simonetti G; Grassi I; Mazza M
Front Oncol; 2020; 10():831. PubMed ID: 32537434
[TBL] [Abstract][Full Text] [Related]
19. Accuracy of grading pancreatic neuroendocrine neoplasms with Ki-67 index in fine-needle aspiration cellblock material.
Grosse C; Noack P; Silye R
Cytopathology; 2019 Mar; 30(2):187-193. PubMed ID: 30303569
[TBL] [Abstract][Full Text] [Related]
20. Can histogram analysis of MR images predict aggressiveness in pancreatic neuroendocrine tumors?
De Robertis R; Maris B; Cardobi N; Tinazzi Martini P; Gobbo S; Capelli P; Ortolani S; Cingarlini S; Paiella S; Landoni L; Butturini G; Regi P; Scarpa A; Tortora G; D'Onofrio M
Eur Radiol; 2018 Jun; 28(6):2582-2591. PubMed ID: 29352378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
